Kiniksa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from devastating and debilitating diseases with significant unmet medical need.
At Booth #2641, Kiniksa will be highlighting efforts related to recurrent pericarditis, a rare autoinflammatory condition with no FDA-approved therapies. Current treatments, utilizing nonspecific inhibitors of inflammation, can result in significant morbidity with chronic use.
The interleukin-1 (IL-1) pathway plays a major role in the pathophysiology of recurrent pericarditis. Rilonacept (KPL-914) is a recombinant fusion protein that blocks IL-1 alpha and IL-1 beta signaling. Kiniksa is evaluating the efficacy and safety of rilonacept in participants with recurrent pericarditis in a trial called RHAPSODY.
RHAPSODY is now enrolling: Phase 3, double-blind, placebo-controlled, randomized withdrawal study with open-label extension (ClinicalTrials.gov Identifier: NCT03737110).
Rilonacept in recurrent pericarditis is an investigational drug.